Scoop has an Ethical Paywall
Arthritis drug funded to treat Covid-19 – Expert Reaction
Arthritis drug tocilizumab will now be funded to treat patients with moderate to severe cases of Covid-19.
The drug is facing massive demand around the world, with its manufacturer Roche no longer able to supply New Zealand with the drug for the next three months. Pharmac has also announced today it will begin funding an alternative drug for people with severe rheumatoid arthritis who have been affected by the shortage.
The SMC asked experts to comment on these announcements.
Dr Colin McArthur, Intensive Care Specialist, Auckland City Hospital, comments:
“There is now strong evidence that tocilizumab reduces mortality from severe COVID-19 and reduces the need for patients to be on a ventilator in intensive care. Given in conjunction with steroid medication such as dexamethasone, this treatment is of great benefit in both improving the outcome for individual patients, but also reducing the demand for intensive care. This combination of treatments works by modifying the body’s immune response, which in some cases can cause severe lung damage. Tocilizumab is only given to patients who are in hospital requiring extra oxygen and have signs of active inflammation.
“The announcement from PHARMAC of specific funding and arrangements to maximise the supply of tocilizumab during a period when there is a global shortage will be welcomed by all those involved in the hospital care of patients with COVID-19. In particular, the ability of this treatment to reduce the need for intensive care is very important for the New Zealand healthcare system.”
Conflict of interest statement: Dr McArthur is a senior author of one of the studies demonstrating the effectiveness of tocilizumab.
Science Media Centre NZ
Our aim is to promote accurate, evidence-based reporting on science and technology by helping the media work more closely with the scientific community.
The Science Media Centre is New Zealand's only trusted, independent source of information for the media on all issues related to science. Thousands of news stories providing context from and quoting New Zealand researchers have been published as a direct result of our work.
Hugh Grant: How To Reduce Network Bottlenecks
Dominion Road Business Association: Auckland Transport's 'Bus To The Mall' Campaign: A Misuse Of Public Funds And A Blow To Local Businesses
Parrot Analytics: A Very Parrot Analytics Christmas, 2024 Edition
Financial Markets Authority: Individual Pleads Guilty To Insider Trading Charges
Great Journeys New Zealand: Travel Down Memory Lane With The Return Of The Southerner
WorkSafe NZ: Overhead Power Lines Spark Safety Call
